| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Grzegorz Kuballa, Przemysław Nowak, Łukasz Labus, Aleksandra Bortel, Joanna Dabrowska, Marek Swoboda, Adam Kwieciński, Richard M Kostrzewa, Ryszard Bru. Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine. Pharmacological reports : PR. vol 57. issue 2. 2006-01-12. PMID:15886414. |
the aim of this study was to examine behavioral and biochemical effects of nafadotride, the new dopamine d3 receptor antagonist, and to compare it with haloperidol (dopamine d2 receptor antagonist) and clozapine (predominate dopamine d4 receptor antagonist). |
2006-01-12 |
2023-08-12 |
rat |
| Grzegorz Kuballa, Przemysław Nowak, Łukasz Labus, Aleksandra Bortel, Joanna Dabrowska, Marek Swoboda, Adam Kwieciński, Richard M Kostrzewa, Ryszard Bru. Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine. Pharmacological reports : PR. vol 57. issue 2. 2006-01-12. PMID:15886414. |
the results of the study indicate that nafadotride, the dopamine d3 receptor antagonist, has a behavioral and biochemical profile of action different from that of haloperidol but partially similar to that of clozapine. |
2006-01-12 |
2023-08-12 |
rat |
| Robert J Barrett, William F Caul, Randy Smit. Withdrawal, tolerance, and sensitization to dopamine mediated interoceptive cues in rats trained on a three-lever drug-discrimination task. Pharmacology, biochemistry, and behavior. vol 81. issue 1. 2005-12-30. PMID:15894057. |
in the present experiment rats were trained on a three-lever, drug-discrimination task to discriminate the cues associated with 0.30 mg/kg of the indirect dopamine (da) agonist, amphetamine (amph), saline (sal), and 0.03 mg/kg of the da, d2 receptor antagonist, haloperidol (hal). |
2005-12-30 |
2023-08-12 |
rat |
| Mark A Osinski, Marie E Uchic, Terese Seifert, Thomas K Shaughnessy, Loan N Miller, Masaki Nakane, Bryan F Cox, Jorge D Brioni, Robert B Morelan. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacology, biochemistry, and behavior. vol 81. issue 1. 2005-12-30. PMID:15894081. |
competitive antagonists of dopamine d2-like receptors (domperidone, haloperidol) dose-dependently blocked the emetic response to pnu95666e, a dopamine d2 receptor selective agonist. |
2005-12-30 |
2023-08-12 |
Not clear |
| Eyassu Chernet, Laura J Martin, Dominic Li, Anne B Need, Vanessa N Barth, Karen S Rash, Lee A Phebu. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life sciences. vol 78. issue 4. 2005-12-15. PMID:16139310. |
intravenous, subcutaneous and oral dose-occupancy curves were generated for haloperidol at the dopamine d2 receptor as were oral curves for the antipsychotic drugs olanzapine and clozapine. |
2005-12-15 |
2023-08-12 |
rat |
| M-B Assié, N Consul-Denjean, W Koek, A Newman-Tancred. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology. vol 75. issue 2. 2005-11-29. PMID:16020947. |
in the striatum, [3h]nemonapride binding was inhibited in a dose-dependent manner with the following order of potency (ed50, mg/kg): nemonapride (0.04), raclopride (0.13), spiperone and risperidone (0.14), haloperidol (0.21), clozapine (7.2) and thioridazine (9.4); in the olfactory lobes: nemonapride (0.03), raclopride and spiperone (0.09), haloperidol (0.10), risperidone (0.15), thioridazine and clozapine (11); in the frontal cortex, only the high affinity dopamine d2 antagonist compounds nemonapride (0.05), haloperidol (0.09), and raclopride (0.12) significantly decreased the binding of [3h]nemonapride. |
2005-11-29 |
2023-08-12 |
rat |
| Marie-Bernadette Assié, Véronique Ravailhe, Valérie Faucillon, Adrian Newman-Tancred. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. The Journal of pharmacology and experimental therapeutics. vol 315. issue 1. 2005-11-28. PMID:15987834. |
haloperidol, nemonapride, and the d2 partial agonists, aripiprazole and bifeprunox, did not significantly alter dopamine release. |
2005-11-28 |
2023-08-12 |
rat |
| Shi-Bing Yang, Felix Major, Lutz F Tietze, Marjan Rupni. Block of delayed-rectifier potassium channels by reduced haloperidol and related compounds in mouse cortical neurons. The Journal of pharmacology and experimental therapeutics. vol 315. issue 1. 2005-11-28. PMID:16014573. |
haloperidol is known as an antagonist of dopamine d2 receptors. |
2005-11-28 |
2023-08-12 |
mouse |
| Junji Ichikawa, Young-Chul Chung, Jin Dai, Herbert Y Meltze. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain research. vol 1052. issue 1. 2005-10-27. PMID:16061211. |
clozapine and risperidone, as well as the anticonvulsant mood-stabilizers, valproic acid (vpa), zonisamide, and carbamazepine, but not the typical apd haloperidol, increase dopamine (da) release in rat medial prefrontal cortex (mpfc). |
2005-10-27 |
2023-08-12 |
rat |
| Takeshi Inoue, Takeshi Izumi, Xiao Bai Li, Yuji Kitaichi, Shin Nakagawa, Tsukasa Koyam. Effect of a dopamine D1/5 receptor antagonist on haloperidol-induced inhibition of the acquisition of conditioned fear. European journal of pharmacology. vol 519. issue 3. 2005-10-25. PMID:16135362. |
this study examined the effects of combined treatment with the typical antipsychotic drug haloperidol and dopamine d1/5 receptor antagonist sch 23390 on the acquisition of contextual conditioned fear (re-exposure to an environment paired previously with inescapable electric footshocks), compared with those of various antipsychotic adjuvants, which may increase the effects of antipsychotic drugs. |
2005-10-25 |
2023-08-12 |
rat |
| Robert B Zipursky, Bruce K Christensen, Zafiris Daskalakis, Irvin Epstein, Paul Roy, Ivana Furimsky, Todd Sanger, Shitij Kapu. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 50. issue 8. 2005-10-04. PMID:16127964. |
treatment response to olanzapine and haloperidol and its association with dopamine d receptor occupancy in first-episode psychosis. |
2005-10-04 |
2023-08-12 |
Not clear |
| E A Del Bel, F S Guimarães, M Bermúdez-Echeverry, M Z Gomes, A Schiaveto-de-souza, F E Padovan-Neto, V Tumas, A P Barion-Cavalcanti, M Lazzarini, L P Nucci-da-Silva, D de Paula-Souz. Role of nitric oxide on motor behavior. Cellular and molecular neurobiology. vol 25. issue 2. 2005-09-01. PMID:16047547. |
acute administration of l-noarg has an additive cataleptic effect with haloperidol, a dopamine d2 antagonist. |
2005-09-01 |
2023-08-12 |
mouse |
| Shinji Eguchi, Satoko Tezuka, Narumi Hobara, Shinji Akiyama, Yuji Kurosaki, Hiromu Kawasak. Vanilloid receptors mediate adrenergic nerve- and CGRP-containing nerve-dependent vasodilation induced by nicotine in rat mesenteric resistance arteries. British journal of pharmacology. vol 142. issue 7. 2005-08-04. PMID:15249421. |
nicotine-induced vasodilation was not inhibited by treatment with 3,4-dihydroxyphenylalanine (dopa) receptor antagonist (l-dopa cyclohexyl ester; 0.001-10 microm), dopamine d1 receptor-selective antagonist (sch23390; 1-10 microm), dopamine d2 receptor antagonist (haloperidol; 0.1-0.5 microm), atp p2x receptor-desensitizing agonist (alpha,beta-methylene atp; 1-10 microm), adenosine a2 receptor antagonist (8(p-sulfophenyl)theophylline; 10-50 microm) or neuropeptide y (npy)-y1 receptor antagonist (bibp3226; 0.1-0.5 microm). |
2005-08-04 |
2023-08-12 |
rat |
| Erik Hjerde, Svein G Dahl, Ingebrigt Sylt. Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. European journal of medicinal chemistry. vol 40. issue 2. 2005-07-26. PMID:15694653. |
a model of the dopamine d2 receptor was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone. |
2005-07-26 |
2023-08-12 |
Not clear |
| C Cristina, G Díaz-Torga, A Baldi, A Góngora, M Rubinstein, M J Low, D Becú-Villalobo. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology. vol 146. issue 7. 2005-07-21. PMID:15817666. |
in wild-type mice, prolonged treatment with the d2r antagonist, haloperidol, enhanced pituitary vegf expression and prolactin release, suggesting that dopamine inhibits pituitary vegf expression. |
2005-07-21 |
2023-08-12 |
mouse |
| Claire Advoka. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain. Essential psychopharmacology. vol 6. issue 2. 2005-07-11. PMID:15765792. |
moreover, after long-term treatment, tolerance develops to haloperidol, but not to clozapine, with regard to the amount of dopamine released in the brain. |
2005-07-11 |
2023-08-12 |
Not clear |
| Jiawei Zheng, Yan Yang, Shaohua Tian, Jin Chen, Fraser A W Wilson, Yuanye M. The dynamics of hippocampal sensory gating during the development of morphine dependence and withdrawal in rats. Neuroscience letters. vol 382. issue 1-2. 2005-07-11. PMID:15911142. |
moreover, the da antagonist haloperidol was used to assess the contribution of dopamine to hippocampal gating induced by morphine. |
2005-07-11 |
2023-08-12 |
rat |
| Diego Centonze, Alessandro Usiello, Cinzia Costa, Barbara Picconi, Eric Erbs, Giorgio Bernardi, Emiliana Borrelli, Paolo Calabres. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 24. issue 38. 2005-07-07. PMID:15385604. |
chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine d2l receptors. |
2005-07-07 |
2023-08-12 |
mouse |
| Diego Centonze, Alessandro Usiello, Cinzia Costa, Barbara Picconi, Eric Erbs, Giorgio Bernardi, Emiliana Borrelli, Paolo Calabres. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 24. issue 38. 2005-07-07. PMID:15385604. |
haloperidol effects were mimicked and occluded in mice lacking both d2l and d2s isoforms of dopamine d2 receptors (d2r-/-), in mice lacking d2l receptors and expressing normal levels of d2s receptors (d2r-/-;d2l-/-), and in mice lacking d2l receptors and overexpressing d2s receptors (d2l-/-). |
2005-07-07 |
2023-08-12 |
mouse |
| Marion Wittmann, Michael J Marino, Darrell A Henze, Guy R Seabrook, P Jeffrey Con. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. The Journal of pharmacology and experimental therapeutics. vol 313. issue 2. 2005-07-05. PMID:15659539. |
we demonstrate that bath application of clozapine but not haloperidol or the selective 5-hydroxytryptamine 2a antagonist mdl100907 [(r)-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluoro-phenyl)ethyl]-4-piperidine methanol] induces a robust potentiation of nmda-evoked currents and of glutamatergic epscs and that this potentiation is dependent on dopamine release and postsynaptic activation of d1 receptors. |
2005-07-05 |
2023-08-12 |
rat |